Compare Quest Diagnostics Inc (DGX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Target Corporation — how do they compare? Quest Diagnostics Inc trades at $204.95 (market cap $22.80B), while Target Corporation trades at $137.55 (market cap $60.86B). The key difference: Target Corporation is far larger — about 2.7× Quest Diagnostics Inc's market cap, and Target Corporation pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| DGX | TGT | |
|---|---|---|
Market Cap | $22.80B | $60.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $141.19 |
52-Week Low | $166.42 | $83.68 |
Enterprise Value | $28.82B | $76.16B |
Dividend Yield | 1.67% | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Target (TGT) trades at $134.77, down 0.27% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company maintains stable revenue around $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent dividend payments of $1.14 and $1.16 per share highlight its shareholder returns, while analyst consensus leans toward a buy rating with a $137 price target.
TGT presents a balanced opportunity with solid fundamentals and moderate valuation, but faces risks from competitive retail pressures and margin compression. Upside is supported by consistent earnings beats and dividend reliability, though investors should monitor consumer spending trends and inventory management challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
